HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 11/21/2012 -- Shares of Aeterna Zentaris (NASDAQ:AEZS) have taken a beating after a busy quarter raising capital. Shares of the company now appear ridiculously undervalued given the simple reason that the firm has more cash in the bank than their shares are worth. As strange as it may seem, the stock is trading at a $50.42M market cap with nearly $48 million in pro forma cash and equivalents. That amount of cash now provides the firm with an ample runway to develop its current pipeline and its next major catalyst should be positive interim analysis data for its lead compound, Perifosine. That event is expected to occur during the first quarter (1Q13). In addition, AEZS is now on track to begin a pivotal trial in endometrial cancer. Management had filed for a SPA (Special Protocols Assessment) with the FDA and analysts expect this trial to move forward in 1Q13 as well.
Should Investor Hold AEZS For Long Term Profit: Check Here To Know More
Shares of Groupon, Inc. (NasdaqNM:GRPN) are trading at $3.37 and is -20.30% from its 50-day Moving Average price of $4.2285 and -51.29% from its 200-day Moving Average price of $6.9192. The average trading volume is 14889600 shares and its market capitalization is $2.210B. Groupon (NASDAQ: GRPN ) jumped as much as 15% following the disclosure from investment firm Tiger Global Management that it purchased a 9.9% stake in the company. According to the SEC filing, Tiger Global Management has acquired an additional 63.7 million shares of Groupon during the latest quarter as the previous SEC filing noted just a 1.3 million share position. This purchase comes just two weeks after Groupon reported third-quarter results which showed a 32% increase in revenue, breakeven EPS, and total cash of $1.2 billion with no debt.
Is GRPN going to move higher as many investors expect : Find Out Here
Regeneron Pharmaceuticals, Inc.(NASDAQ:REGN), a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. The company has a P/E ratio of 80, above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Regeneron as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Regeneron Pharmac (NasdaqNM:REGN) is +12.43 - +7.75% from the previous close of $160.44. It traded between $159.73 - 174.60 with total traded volume of 1909091 shares. At Current Market Price, REGN is in distance of +13.22% from its 50-day Moving Average price of $152.679 and +25.88% from its 200-day Moving Average price of $137.331.
Can REGN Continue To Move Higher? To Know More CHECK HERE
Up nearly 7% in pre-market trading, ZIP (NASDAQ:ZIP) was raised to "buy" from "neutral" at Goldman Sachs ahead of the opening bell. However, the equity has surrendered roughly 61% from the year-ago period, which may be attracting some bearish speculation. Short interest on ZIP rose by 2% during the past two reporting periods, and now accounts for a hefty 19% of the security's available float. In fact, it would take a whopping 32 days to unwind these pessimistic bets, at the stock's average daily trading volume. Zipcar, Inc. (NasdaqNM:ZIP) is +0.50 - +7.11% from the previous close of $7.03. It traded between $7.34 - 7.75 with total traded volume of 899190 shares. At Current Market Price, ZIP is in distance of +8.40% from its 50-day Moving Average price of $6.9465 and -15.46% from its 200-day Moving Average price of $8.9074.
Should Investor Hold Or book PRofit From ZIP : Should Investor Watch Now
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)